HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 6,433-6,444 of 27,277
Drug study icon
CompletedNCT05407064

A Dose-Finding Study of MM120 (LSD D-Tartrate) for Anxiety Symptoms

Official study title

A Phase 2, Multi-center, Randomized, Double-Blind, Parallel-Group, Dose-Finding Study to Assess the Effect of Four Doses of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
AnxietyMedication studyAges 18–74
Countries
United States
Sponsor
Definium Therapeutics US, Inc.
Drug study icon
CompletedNCT01451164

A Dose-finding study of OPC-34712 in people with Schizophrenia

What is this study about?

Researchers compared OPC-34712 and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

In Kanto Region
SchizophreniaMedication studyAges 18–65
Countries
Japan
Sponsor
Otsuka Pharmaceutical Co., Ltd. (Pharmaceutical company)
Drug study icon
CompletedNCT00796835

A Dose-proportionality Study of Five Tablet Strengths of ER OROS Paliperidone

Official study title

Dose-proportionality Study of the Five ER OROS Paliperidone To-be-marketed Tablet Strengths (3, 6, 9, 12, and 15 mg) in Healthy Male Subjects

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT06653296

A Dose-Response Safety Study of ENX-102 in people with GAD

What is this study about?

Researchers compared ENX-102 and placebo, tracking side effects to assess safety and tolerability in people with an anxiety condition.

This study has finished and is no longer accepting participants.

Multiple locations, including Liverpool
AnxietyMedication studyAges 18–65
Countries
United Kingdom
Sponsor
Engrail Therapeutics INC
Drug study icon
CompletedACTRN12619000569101

A dose-response study of scopolamine in major depressive disorder

Official study title

A randomised, double-blind, active placebo-controlled, parallel groups dose-response study of intravenous scopolamine in major depressive disorder

This study has finished and is no longer accepting participants.

In New Zealand
DepressionInterventional studyAges 18–60
Countries
New Zealand
Sponsor
The University of Auckland
Drug study icon
CompletedNCT01996644

A Double Blind study of DCS for Food Anxiety

Official study title

A Double Blind Clinical Trial of DCS for Food Anxiety for Patients With Anorexia and Bulimia Nervosa

This study has finished and is no longer accepting participants.

In St Louis
Eating disorders, AnxietyMedication studyAges 14–65
Countries
United States
Sponsor
Washington University School of Medicine
Drug study icon
UnknownNCT01426984

A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults

Official study title

A Double Blind Crossover Study on the Effect of Methylphenidate on Decision-making Ability of Adults With Borderline Personality Disorder (BPD) Compared to Adults With Attention Deficit Hyperactivity Disorder (ADHD) and Healthy Adults

Current recruitment status is unconfirmed.

In Hod HaSharon
Personality disorders, ADHDMedication studyAges 21–50
Countries
Israel
Sponsor
Shalvata Mental Health Center

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.